Oxaprozin

Quick links to important sections

Oxaprozin

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Oxaprozin

What is Oxaprozin?

Oxaprozin is a medication belonging to the class of drugs known as nonsteroidal anti-inflammatory drugs (NSAIDs). It is primarily used to manage symptoms associated with various forms of arthritis and other inflammatory conditions. Unlike some other medications in its class that require multiple doses throughout the day, oxaprozin is notable for its long half-life, which often allows for once-daily administration.

Mechanism of Action

Oxaprozin works by inhibiting the activity of enzymes known as cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). These enzymes play a critical role in the production of prostaglandins, which are lipid compounds in the body that act as mediators for inflammation, pain, and fever. By reducing the synthesis of these prostaglandins, oxaprozin helps to decrease swelling, joint stiffness, and physical discomfort.

Therapeutic Use

The medication is commonly utilized for the long-term treatment of chronic inflammatory joint diseases. Its primary applications include:

  • Osteoarthritis: A degenerative joint disease characterized by the breakdown of joint cartilage and underlying bone.
  • Rheumatoid Arthritis: An autoimmune disorder that primarily affects the joints, leading to painful swelling and potential joint erosion.
  • Juvenile Rheumatoid Arthritis: A form of arthritis that affects children, where oxaprozin may be used to improve mobility and reduce systemic inflammation.

As a systemic treatment, oxaprozin focuses on managing the symptoms of these conditions rather than providing a cure. Its role is to facilitate better physical function and improve the quality of life for individuals dealing with chronic musculoskeletal pain.

Regulatory References

  1. Oxaprozin Drug Information (MedlinePlus, NIH)

What side effects are possible with Oxaprozin?

Possible Side Effects and Safety Information

The safety profile of Oxaprozin, a Nonsteroidal Anti-inflammatory Drug (NSAID), is characterized by potential adverse reactions across several major body systems, as documented in official regulatory labeling.


Common Adverse Reactions

Reactions classified as common (occurring in 1% or more of patients in clinical data) frequently involve the Gastrointestinal (GI) and Nervous Systems. These include dyspepsia (indigestion), nausea, abdominal pain, diarrhea, and constipation. Nervous System Disorders that are commonly documented include dizziness, headache, and somnolence. Reactions like tinnitus (ringing in the ears) and rash are also listed in this frequency category.


Serious Safety Risks and Constraints

The regulatory profile highlights risks of serious adverse reactions that can be fatal and may occur without warning. These include an increased risk of serious cardiovascular thrombotic events (such as myocardial infarction and stroke) and severe GI adverse reactions, including bleeding, ulceration, and perforation of the stomach or intestines. The risk of these serious events may increase with the duration of use.

Serious reactions involving the skin, such as Stevens-Johnson Syndrome (SJS), and severe liver reactions (hepatotoxicity) are also documented concerns. Oxaprozin is strictly contraindicated for the treatment of peri-operative pain during Coronary Artery Bypass Graft (CABG) surgery and in patients with a history of aspirin-sensitive asthma. Older adults are noted to be at a greater risk for serious GI adverse events.

Overdose and Emergency Response

Overdose and When to Seek Help

Suspected overdose with Oxaprozin requires immediate medical attention. Government regulatory documents define the overdose profile primarily by its documented manifestations and the urgent need for professional intervention, as no specific antidote is known for this medication.

Overdose Manifestation
Lethargy, Drowsiness
Nausea, Vomiting
Epigastric Pain, Headache

Overdose cases may present with central nervous system effects such as lethargy and drowsiness, and gastrointestinal signs including nausea, vomiting, and epigastric pain. Regulatory bodies warn that severe or life-threatening outcomes are possible, including seizures, coma, hypotension (low blood pressure), and, rarely, acute renal failure or metabolic acidosis. The risk of severity may be increased in patients with pre-existing renal or hepatic impairment.

When an overdose is suspected, it is mandatory to seek emergency medical attention immediately and contact emergency services or a Poison Control Center. Management of overdose involves symptomatic and supportive treatment under close clinical observation, which includes monitoring of renal and hepatic function. Procedural interventions, such as the use of activated charcoal or gastric lavage, may be considered if the ingestion was recent.

Therapeutic Uses of Oxaprozin

Oxaprozin is commonly used to provide symptomatic relief across conditions involving inflammatory or irritative states, assisting in addressing symptoms that interfere with daily functioning. This medication is primarily relevant for managing the signs and symptoms of major chronic conditions such as Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis.

The medication also plays a role in managing the symptoms of Juvenile Rheumatoid Arthritis (JRA) in specific pediatric patients and is applied when appropriate for easing the disruptive manifestations of primary dysmenorrhea (menstrual pain). In these contexts, it is relevant for easing temporary functional strain and heightened symptoms. The medication may offer supportive relief that helps patients cope more steadily with symptom fluctuations.

Oxaprozin helps ease the overall symptom burden of persistent issues like joint swelling, stiffness, and chronic pain, which may support better functional stability and day-to-day comfort. It is also applied in clinical settings where short-term symptomatic assistance is needed for mild to moderate acute pain, such as postoperative dental pain.

Quick Fact: Supportive Relief for Symptoms of Inflammatory Joint Pain

Regulatory References

  1. NIH DailyMed drug label

Eligibility and Restrictions for Use

Eligibility for Oxaprozin Use

Official regulatory documents define strict criteria for who is eligible to use Oxaprozin, focusing on patient history, specific comorbidities, and age.

Classification Populations Who Must Not Use
Contraindicated Known hypersensitivity to oxaprozin or NSAIDs (including aspirin-sensitive asthma).
Treatment of peri-operative pain in the setting of CABG surgery.
Pregnant women starting at mathbf30 weeks gestation and later.
Avoid Use Patients with severe heart failure or advanced renal disease (unless benefits outweigh risks).
Age-Based Eligibility Status
Adults (mathbfge 16 years) Established for standard indications.
Children (mathbf6 mathbf- mathbf16 years) Established for Juvenile Rheumatoid Arthritis (JRA) only.
Children (mathbf< 6 years) Safety and efficacy not established.

Use is restricted from 20 to 30 weeks gestation, and data regarding use during lactation is insufficient. Elderly patients require caution due to increased sensitivity and risk for serious gastrointestinal events.

What should I know about interactions with other medicines?

Oxaprozin Interactions with other medicines and products

Official regulatory information for Oxaprozin documents specific drug-drug and drug-substance interactions that fall into pharmacodynamic (PD) and pharmacokinetic (PK) classifications.

Documented Pharmacokinetic Interactions

Oxaprozin's co-administration can affect the plasma concentration of other medicines by reducing their renal clearance, potentially increasing their exposure and toxicity. This interaction pattern is explicitly documented for several agents.

Interacting Substance Documented Effect on Co-administered Drug
Lithium Increases serum lithium concentrations and reduces renal clearance.
Digoxin Increases serum digoxin concentration and prolongs its half-life.
Methotrexate Increases serum methotrexate concentration and may increase toxicity.
Pemetrexed Increases risk of Pemetrexed-related toxicity (myelosuppression, renal, GI).

Documented Pharmacodynamic Interactions

Co-administration with Oxaprozin may lead to PD conflicts that diminish the effectiveness of co-administered agents. The medicine may diminish the antihypertensive effect of ACE Inhibitors, ARBs, and Beta-blockers, and can reduce the natriuretic effect of Diuretics (Loop and Thiazides). Combining Oxaprozin with Cyclosporine may increase the risk of cyclosporine nephrotoxicity.

Interaction-Related Restrictions

Official labeling contains specific restrictions and prohibitions. Oxaprozin is formally contraindicated for treating peri-operative pain in the setting of CABG surgery. It is also not generally recommended for co-administration with analgesic doses of Aspirin due to the increased risk of serious gastrointestinal events. The label notes that the interaction with ACE Inhibitors and ARBs results in amplified renal deterioration risk for elderly, volume depleted, or renally impaired patients.

Mechanism of Action

Oxaprozin is a nonsteroidal anti-inflammatory drug (NSAID) that exerts its primary effects by influencing specific enzymatic signaling pathways. Its action fundamentally involves regulating mediator synthesis, which subsequently alters physiological responses.


Inhibition of Cyclooxygenase (COX) Enzymes

This domain covers Oxaprozin’s primary mechanism: the non-selective inhibition of both COX-1 and COX-2 enzymes. This action blocks the conversion of arachidonic acid into prostaglandins, prostacyclins, and thromboxanes, which are lipid mediators. The inhibition results in a decreased synthesis of these eicosanoids.


Modulation of Eicosanoid Signaling Cascade

Oxaprozin modifies the early molecular steps within the arachidonic acid cascade, thereby limiting the transmission of eicosanoid-mediated downstream signaling. By reducing the synthesis of these lipid mediators, the mechanism modifies the kinetics of heightened physiological responses influenced by eicosanoid concentration.


Influence on Systemic Physiological Processes

The mechanistic effects extend systemically, as Oxaprozin engages pathways that regulate dysregulated physiological processes. This action results in a diminished concentration of mediators throughout biological systems. The engagement of this mechanism results in an alteration of targeted pathway activity.

Dosage and Administration Information

How to Use Oxaprozin

Oxaprozin is a nonsteroidal anti-inflammatory drug (NSAID) prescribed for oral administration. Following established instructions is essential for proper use.


Dosing and Administration

Administration Scope Detail
Route of Administration Oral (by mouth) only.
Dosing Frequency Typically once daily (QD). Divided doses may be used if a patient cannot tolerate a single daily dose.
Standard Adult Dose 1,200 mg once daily for conditions such as osteoarthritis or rheumatoid arthritis.
Maximum Daily Dose Generally not to exceed 1,200 mg; however, some guidelines allow up to 1,800 mg in divided doses for severe disease, where clinically appropriate and with close monitoring.
Administration Conditions The tablet or capsule must be swallowed whole with liquid. Do not crush, chew, or divide the dose. It may be taken with food, although this may affect the rate of absorption.

Population-Specific Use

Special attention to dosage is required for certain patient groups:

  • Initial Dose: A lower starting dose of 600 mg once daily is recommended for patients with low body weight or those with mild to moderate renal impairment.
  • Pediatric Use: For Juvenile Rheumatoid Arthritis (JRA), specific weight-based dosing applies (e.g., 600 mg to 1,200 mg daily for children aged 6 years and older). Safety and effectiveness have not been established for children under 6 years of age.

Use Protocol

Therapy should always be initiated with the lowest effective dosage and continued for the shortest duration necessary to align with treatment goals. The prescribed dose should not be altered without instruction from a healthcare provider. Due to its long half-life, the full effect of Oxaprozin may require several days of continuous administration to reach steady state.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Oxaprozin

This section provides a summary of the available research on Oxaprozin, describing the types of studies that have been conducted, the outcomes that were measured, and the limitations or uncertainties that remain in the evidence base. This information is intended to contextualize the drug's use and should not be considered medical advice.


Evidence for Use in Osteoarthritis (OA)

Research exploring outcomes related to symptoms associated with osteoarthritis has primarily involved short-term randomized controlled trials (RCTs) and comparative studies. These study designs were used to explore patient-reported outcomes when compared to either an inactive substance or other research-examined medications. Studies focused on evaluating specific outcomes related to physical discomfort and daily functioning in adults with osteoarthritis. Outcomes related to measures of pain scores and functional status were examined. Long-term effects are not fully established because follow-up durations were limited in many of the core studies.


Evidence for Use in Rheumatoid Arthritis (RA)

Oxaprozin was studied for outcomes related to rheumatoid arthritis (RA) symptoms through randomized controlled trials and comparative studies in adults. Research examined outcomes linked to inflammatory states, focusing specifically on traditional measures of RA disease activity, such as changes in tender joint count and swollen joint count. Subgroup findings are uncertain concerning patients with different stages of RA. The available data largely covers short-term usage, and studies contribute to the broad evidence landscape.


Evidence in Special Populations and Uncertainties

The research available for juvenile rheumatoid arthritis (JRA) in pediatric patients (children aged 6 to 16 years) is less extensive, relying on population pharmacokinetic research and extrapolation from adult RA studies. The evidence basis for use in children remains low. Specific research has been studied for the pediatric population and studies observed use in elderly adults.

Key limitations in the current evidence base include the limited follow-up durations of many studies, meaning long-term effects are not fully established. Comparative evidence is lacking in some areas, and evidence derived from settings with varying symptom burdens over long periods is generally insufficient. Research is ongoing to further contribute to the broad evidence landscape.

Frequently Asked Questions (FAQ)

Common questions about Oxaprozin (FAQ)

Q: Is Oxaprozin the same as other pain relievers like ibuprofen?

A: Oxaprozin is in the same class of medicines as ibuprofen, known as non-steroidal anti-inflammatory drugs (NSAIDs). According to official product information, a key distinction is its long half-life in the body, a property that supports its common prescription for once-daily dosing.

Q: How quickly does Oxaprozin start to work after taking it?

A: Pharmacokinetic studies indicate that the highest concentration of the medicine in the blood is usually reached about 3 to 5 hours after a single oral dose. However, due to its long half-life, the full, steady therapeutic effect may require several days of continuous administration to be achieved.

Q: What is the longest time someone can take Oxaprozin safely?

A: Official information emphasizes using the drug for the shortest duration necessary to manage symptoms, as the risk of serious side effects, particularly those involving the heart and stomach, may increase with the duration of use. Clinical studies cited in official labeling have generally gathered data on usage for periods up to three years.

Q: Can Oxaprozin be taken by people with high blood pressure?

A: NSAIDs, including Oxaprozin, can cause new or worsen existing high blood pressure (hypertension). Regulatory documents advise that the medicine should be used with caution in patients with this condition, and official documents advise that blood pressure monitoring is necessary during therapy.

Q: Can Oxaprozin affect the way blood clots?

A: Official documentation notes that Oxaprozin, like other NSAIDs, can interfere with agents that affect hemostasis, which is the body's natural process for stopping blood flow and clotting. For patients using the drug along with blood thinners, the regulatory labeling states that close monitoring is required.

Q: Is there a generic version of Oxaprozin available?

A: Yes, regulatory listings show that Oxaprozin is available from multiple manufacturers as a generic equivalent. These are required to meet the same regulatory standards for quality and effectiveness as the brand-name product.

Q: Does Oxaprozin have a potential for dependency or addiction?

A: No, official regulatory agencies, such as the Drug Enforcement Administration (DEA), have not classified Oxaprozin as a controlled substance. This classification is reserved for medications with a recognized potential for abuse or dependence.

Q: What is the difference between Oxaprozin and naproxen?

A: Both medicines belong to the same pharmacological class: NSAIDs. A key feature of Oxaprozin described in official information is its extended half-life compared to naproxen, which means it stays in the body longer and supports its common once-daily prescription.

Q: Is Oxaprozin used for general body aches or only for specific conditions?

A: Oxaprozin is officially approved to manage the signs and symptoms of specific chronic inflammatory conditions. These established indications include osteoarthritis (OA), rheumatoid arthritis (RA), and juvenile rheumatoid arthritis (JRA).

Q: How is Oxaprozin different from acetaminophen (Tylenol)?

A: Oxaprozin is an NSAID with anti-inflammatory effects, working to reduce swelling as well as pain and fever. Official documents indicate that acetaminophen provides pain relief and fever reduction but does not have significant anti-inflammatory activity.

Q: Are there any foods or drinks that should be avoided with Oxaprozin?

A: Yes, official warnings specifically state that consuming alcohol while taking Oxaprozin can significantly increase the risk of serious side effects, such as gastrointestinal bleeding and ulcers. The medicine may be taken with food, but this may affect how fast it is absorbed.

Q: Does Oxaprozin have a 'black box warning' from the FDA?

A: Yes, the official prescribing information includes a Boxed Warning, which is the most serious type of caution issued by the FDA. This warning highlights the potential for serious, life-threatening cardiovascular and gastrointestinal adverse events.

Q: What is the half-life of Oxaprozin?

A: According to official pharmacokinetic studies, the average elimination half-life of Oxaprozin in adults is reported to be approximately 54.9 hours. This notably long half-life is the reason it is often prescribed for once-daily use.

Q: What if I'm already taking a blood thinner, can I use Oxaprozin?

A: Official documentation indicates that taking Oxaprozin with anticoagulants (blood thinners), such as warfarin, increases the overall risk of bleeding. Official documentation indicates that when these medicines are used together, close monitoring for signs of bleeding is required.

Q: Can Oxaprozin interact with alcohol?

A: Yes, official warnings indicate that drinking alcohol while using Oxaprozin can significantly increase the risk of developing serious gastrointestinal side effects, including stomach bleeding and ulcers.

Q: Are there different brand names for the drug Oxaprozin?

A: Yes, while the active ingredient is Oxaprozin, it has historically been marketed under different brand names, such as Daypro. Today, both the brand-name product and generic versions are available.

Q: Can Oxaprozin cause dizziness or affect driving?

A: Official reports list dizziness and somnolence (drowsiness) as common adverse reactions. Patients should be aware that if they experience these effects, their ability to perform activities requiring alertness, such as driving or operating machinery, may be diminished or affected.

Q: What should be done if an allergic reaction to Oxaprozin is suspected?

A: Official warnings state that severe allergic reactions, known as anaphylactoid reactions, can occur with this medication. The regulatory warning indicates that if such a reaction occurs, emergency medical help should be sought immediately.

Q: Is Oxaprozin a controlled substance?

A: No, regulatory information confirms that Oxaprozin is not listed by the Drug Enforcement Administration (DEA) as a controlled substance. It does not carry the potential for abuse or dependency associated with controlled substances.

Q: What does 'contraindicated' mean in relation to Oxaprozin?

A: 'Contraindicated' is a term used in official regulatory documents meaning that the medicine is medically restricted from use by patients with certain specific conditions, as the risks clearly outweigh any potential benefits. Oxaprozin has several listed contraindications.

Q: Are there specific tests needed before starting Oxaprozin?

A: Official documentation advises that monitoring of renal (kidney) and hepatic (liver) function may be appropriate before and during therapy in certain high-risk patients. This is often recommended for those with existing conditions such as heart failure, dehydration, or renal impairment.

Q: How is the long-term safety of Oxaprozin monitored?

A: The official product information advises that the long-term safety is monitored by checking for serious risks. This monitoring may include checking blood pressure, watching for signs of internal bleeding, and regularly monitoring renal (kidney) and hepatic (liver) function in certain high-risk patients.

Q: Is Oxaprozin a strong painkiller?

A: Oxaprozin is officially classified as an analgesic (pain reliever) and an anti-inflammatory agent that works by reducing the body's production of pain and inflammation mediators. Its use is established for managing the symptoms of conditions like osteoarthritis and rheumatoid arthritis.

Q: Can men and women use Oxaprozin in the same way?

A: For adult patients, there are no differences specified in the typical dosing or use protocol between men and non-pregnant women. However, official regulatory documents note that specific restrictions apply to pregnant women starting at 20 weeks gestation and later.

Q: Can Oxaprozin be used for pain after minor surgery?

A: Oxaprozin is explicitly contraindicated for treating peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. General use for pain from minor, non-CABG procedures is not listed as an approved use.

Q: Can Oxaprozin affect kidney function?

A: Yes, NSAIDs, including Oxaprozin, carry a risk of renal (kidney) toxicity. Official documents state that use should be avoided in patients with advanced renal disease unless the benefits are clearly determined to outweigh the risk of worsening kidney function.

Q: Can a person with a history of stomach ulcers use Oxaprozin?

A: Official warnings state that patients with a prior history of peptic ulcer disease and/or gastrointestinal bleeding are at a greater risk for serious stomach and intestinal events if they take Oxaprozin. This is an important factor described in the regulatory warnings.

Q: Can Oxaprozin affect liver test results?

A: Yes, Oxaprozin is associated with a risk of serious liver reactions (hepatotoxicity). Official labeling advises that the medication should be stopped if abnormal liver test results persist or worsen, or if clinical signs of liver disease develop.

How should Oxaprozin be stored and disposed of?

How to Store and Dispose of Oxaprozin

Oxaprozin tablets must be stored at Controlled Room Temperature ( 20 C to 25 C / 68 F to 77 F), with temporary excursions permitted up to 30 C. The medication must be protected from heat, moisture, and freezing.

Container and Protection

Storage requires keeping the medication in its original, tightly closed, light-resistant container. This container must have a child-resistant closure. The medicine must always be kept out of the reach of children.

Disposal

Do not flush unused or expired Oxaprozin down the toilet. Disposal should adhere to official guidelines, such as utilizing a drug take-back program. If a program is unavailable, mix the tablets with an unappealing substance, seal the mixture in a bag, and discard it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Oxaprozin found in:

A-Z Index: